Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 10—October 2021
Research

Bloodstream Infection Risk, Incidence, and Deaths for Hospitalized Patients during Coronavirus Disease Pandemic

Bhavarth S. ShuklaComments to Author , Prem R. Warde, Eric Knott, Sebastian Arenas, Darryl Pronty, Reinaldo Ramirez, Arely Rego, Miriam Levy, Martin Zak, Dipen J. Parekh, Tanira Ferreira, and Hayley B. Gershengorn
Author affiliations: University of Miami Health System, Miami, Florida, USA (B.S. Shukla, P.R. Warde, S. Arenas, D. Pronty, R. Ramirez, A. Rego, M. Levy, D.J. Parekh, T. Ferreira, H.B. Gershengorn); University of Miami Miller School of Medicine, Miami (B.S. Shukla, E. Knott, M. Zak, D.J. Parekh, T. Ferreira, H.B. Gershengorn); Albert Einstein College of Medicine, Bronx, New York, USA (H.B. Gershengorn)

Main Article

Table 3

Subgroup analysis of clinical variables in patients who had COVID-19 and bloodstream infection risk, incidence, and deaths for hospitalized patients during coronavirus disease pandemic, Miami, Florida, USA, March 25‒October 27, 2020*

Characteristic
LCBI

LCBI HAI

CLABSI
OR (95% CI)
p value
OR (95% CI)
p value
OR (95% CI)
p value
Sex
M 1.84 (0.96‒3.61) 0.068 2.09 (1.07‒4.23) 0.034 3.50 (1.29‒10.7) 0.019
F
0.54 (0.28‒1.04)
0.068

0.48 (0.24‒0.93)
0.034

0.29 (0.09‒0.77)
0.019
Age, y
0.97 (0.94‒1.00)
0.03

0.97 (0.94‒1.00)
0.029

0.99 (0.94‒1.03)
0.6
BMI, kg/m2
0.99 (0.94‒1.04)
0.7

0.99 (0.95‒1.05)
0.8

0.98 (0.91‒1.05)
0.5
Comorbidity index
1.00 (0.98‒1.03)
0.9

1.00 (0.97‒1.02)
0.8

0.97 (0.93‒1.00)
0.094
Previous urethral catheter 1.96 (0.75‒5.18) 0.2 1.99 (0.74‒5.41) 0.2 1.60 (0.28‒10.2) 0.6
Previous central line 8.11 (2.40‒37.3) 0.002 11.7 (2.94‒78.2) 0.002 NA NA
Previous mechanical ventilation 2.82 (0.91‒9.89) 0.086 2.18 (0.70‒7.44) 0.2 ∞ (0.00‒∞) >0.9
Previous steroid treatment 0.91 (0.40‒2.14) 0.8 0.91 (0.39‒2.21) 0.8 1.42 (0.35‒6.73) 0.6
Previous ICU admission 2.47 (0.74‒7.61) 0.12 3.56 (1.07‒11.5) 0.034 0.00 (0.00‒∞) >0.9
Previous dialysis
1.01 (0.46‒2.14)
>0.9

0.95 (0.43‒2.07)
>0.9

0.59 (0.20‒1.68)
0.3
Prone positioning
1.09 (0.49‒2.37)
0.8

1.21 (0.55‒2.69)
0.6

2.02 (0.64‒6.97)
0.2
Remdesivir treatment 1.58 (0.78‒3.24) 0.2 1.58 (0.76‒3.32) 0.2 1.29 (0.45‒3.77) 0.6
Tocilizumab treatment
1.29 (0.42‒3.77)
0.6

1.23 (0.39‒3.62)
0.7

1.10 (0.25‒4.44)
0.9
SOFA score imputed 1.00 (0.86‒1.14) >0.9 0.96 (0.82‒1.10) 0.6 0.083 (0.63‒1.03) 0.12

*Model also adjusted for race/ethnicity and payer (these variables had no major association with outcomes). BMI, body mass index; CLABSI, central line‒associated bloodstream infection; ICU, intensive care unit; LCBI, laboratory‒confirmed bloodstream infection; NA, not applicable; SOFA, sequential organ failure assessment.

Main Article

Page created: July 15, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external